Followers | 263 |
Posts | 32966 |
Boards Moderated | 2 |
Alias Born | 01/24/2013 |
Wednesday, November 01, 2023 8:38:57 AM
Will probably to continue to hold and add along the way.
That presentation they gave yesterday in Berlin, might just bear some fruit.
So much of their work is in the early stage time frame, that I wonder about a buyout of the technology.
I'll look into their history in that regards.
A sure sign that the debate has been won:
When the response is an attack against the other person.
Recent OMGA News
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 11:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:04:21 AM
- Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/06/2024 11:00:02 AM
- Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/23/2024 11:00:02 AM
- Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control • GlobeNewswire Inc. • 04/09/2024 11:00:31 AM
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update • GlobeNewswire Inc. • 03/28/2024 01:15:05 PM
- Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:14:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:00:18 PM
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 09:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 12/04/2023 09:00:22 PM
- Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders • PR Newswire (US) • 11/28/2023 12:01:00 AM
- Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics • PR Newswire (US) • 11/21/2023 11:00:00 AM
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 09:00:00 PM
- Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis • GlobeNewswire Inc. • 11/13/2023 12:00:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:03:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:03:00 PM
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 11/09/2023 12:00:17 PM
- Omega Therapeutics to Participate in The Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/07/2023 09:00:20 PM
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller • GlobeNewswire Inc. • 10/31/2023 11:00:16 AM
- Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC • GlobeNewswire Inc. • 10/16/2023 11:00:46 AM
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM